OBJECTIVES: To develop an analysis that compares the use of Vedolizumab, as a first-line biological therapy in the treatment of Ulcerative Colitis, compared to the Biological therapies currently used, and based on the results reported in the different clinical studies of each treatment.

METHODS: A probabilistic decision tree was constructed where the four biological first-line therapy choices for UC are presented, including the option to use vedolizumab. We use a representative patient who can start in any line of treatment to make a comparison, subtotals are obtained for the costs of induction and maintenance, as well as the respective induction costs generated in the case of primary or secondary treatment failure. The result is the total cost reached to take patients to respond for a year to a treatment, or otherwise to fail with the initial decision and with the second line of treatment suggested in this model. This total cost is assigned to the treatment initially chosen, and there is also a result of the number of patients who did not respond in the algorithm and who, under the assumption of the model, would go to colectomy, drugs costs are obtained from SISMED, all clinical related costs were obtained from the SOAT fare manual 2011 + inflation reported by the government.

RESULTS: After simulating a one patient cohort for each choice, the total economic cost in the first arm (VDZ) was USD 18.243, the results for IFX, ADA, and GOL was $22.859, $21.134, $31.027 respectively. Then VDZ was at least 15,8% a less expensive option than the second lowest cost option.

CONCLUSIONS: Vedolizumab demonstrates from the economic point of view, to be a favorable option for the health system as the first line of treatment for UC, likewise this result is accompanied by important favorable clinical results.